During a Case-Based Roundtable® event, Virginia G. Kaklamani, MD, discussed the use of datopotamab deruxtecan in patients with advanced breast cancer and how next-generation sequencing plays an important role in their treatment in the second article of a 2-part series.
CASE SUMMARY
Two Years After Completing Adjuvant Therapy
After 16 Months on Treatment
After 10 Months on Treatment
After 8 Months on Treatment
Targeted Oncology: What results stood out to you from the phase 3 TROPION-Breast01 trial (NCT05104866) for patients with HR-positive, HER2-negative, or HER2-low breast cancer who were given datopotamab deruxtecan (Dato-DXd)?
VIRGINIA G. KAKLAMANI, MD: The median progression-free survival [PFS] for patients on chemotherapy was 4.9 months [95% CI, 4.2-5.5] compared with those on Dato-DXd at 6.9 months [95% CI, 5.7-7.4], so this was a 2-month improvement that was statistically significant [HR, 0.63; 95% CI, 0.52-0.76; P < .0001].1
We are still waiting for overall survival [OS] results, as it was a pretty early presentation, but there was a hint of improvement in OS [with a median follow-up of 9.7 months and HR of 0.84 (95% CI, 0.62-1.14) in the Dato-DXd arm]. The overall response rate increased from 23% [in the chemotherapy arm] to 36% [in the Dato-DXd arm]. This therapy was also relatively well tolerated as few patients had to have dose reductions and very few had to have a dose discontinuation.1
What adverse event (AE) outcomes were notable from this study?
The rate of neutropenia [at any grade] with Dato-DXd was lower than [for the patients receiving] chemotherapy at 39% [vs 42%, respectively].1 Most of these neutropenia cases were grade 1 and 2, with just 1% of patients having grade 3 neutropenia or higher on Dato-DXd [compared with 31% in the chemotherapy arm].
The one AE [to note] was dry eyes…. On the trial patients were mandated to see the ophthalmologist. I don't know if eventually we're going to need to have an ophthalmologist seeing our patients [during treatment with Dato-DXd], and I know that's one of the limitations [with this therapy] as it's not that easy to get [the patient in] to see an ophthalmologist.
Drug-related interstitial lung disease [ILD] was seen in 3 patients on Dato-DXd, and 2 patients just had grade 1 and 2 ILD.1 So, it's interesting that even though the payload is the same [as the chemotherapy] the rate of toxicity is different, and I was surprised with the low rate of neutropenia.
How do you incorporate NGS into your treatment plan for these patients?
I think that NGS should be part of our standard of care, and what I'll typically do is order NGS on the biopsy [right away]. The companies now, even with bone marrow biopsies, can give us good results for NGS, which is wonderful. We just need to tell the pathologist [what we are looking for] before they process the tissue. I will typically wait and get the ctDNA [collected] at disease progression, because that's when we start seeing more ESR1 mutations.
The rate of ESR1 mutations in that initial presentation of metastatic disease is probably around 5%, but at disease progression we see it gets up to 40%.2 Every once in a while, I'll repeat a tissue biopsy, but I'll typically not repeat it as much for the NGS testing, where I'll repeat it to see what the biomarkers [in the patient’s disease] are doing. We need to find out if [the disease] is still ER-positive. Did it switch to HER2-negative or HER2-positive, at this point? So, I'll do that if my treatment response doesn't make sense.
[For example], if I have a patient with a tumor that seems to be ER-positive, and suddenly I get [them on] a duration of a CDK4/6 inhibitor for 6 or 8 months, I'll feel that I'm probably missing something [if there isn’t a response]. That's when I might repeat the tissue biopsy just to see how this tumor has evolved, but the bottom line is that NGS testing has become extremely important. These drugs are expensive, and while they're available [for patients], the only way for us to be able to use them is to know what the mutational background of [the patient's tumor is].
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More